Navigation Links
Cancer stem cells isolated from kidney tumors

Scientists have isolated cancer stem cells that lead to the growth of Wilms' tumours, a type of cancer typically found in the kidneys of young children. The researchers have used these cancer stem cells to test a new therapeutic approach that one day might be used to treat some of the more aggressive types of this disease. The results are published online in EMBO Molecular Medicine.

"In earlier studies, cancer stem cells were isolated from adult cancers of the breast, pancreas and brain but so far much less is known about stem cells in paediatric cancers," remarked Professor Benjamin Dekel, head of the Pediatric Stem Cell Research Institute and a senior physician at the Sheba Medical Center and the Sackler School of Medicine at Tel Aviv University, Israel. "Cancer stem cells contain the complete genetic machinery necessary to start, sustain and propagate tumour growth and they are often referred to as cancer-initiating cells. As such, they not only represent a useful system to study cancer development but they also serve as a way to study new drug targets and potential treatments designed to stop the growth and spread of different types of cancer." He added: "We have demonstrated for the first time the presence of cancer stem cells in a type of tumour that is often found in the kidneys of young children."

Wilms' tumours are the most prevalent type of tumour found in the kidneys of children. While many patients respond well if the tumours are removed early by surgery and if patients are given chemotherapy, recurrences may occur and the cancer can spread to other tissues increasing the risks to the health of the patient. Conventional chemotherapy is toxic to all cells in the body and if given to children may lead to the development of secondary cancers when they become adults. Scientists are looking for ways to ensure that drugs are targeted specifically to tumour cells and some cells in a tumour may be more important to eradicate than others.

The researchers were able to remove parts of the tumours of cancer patients and graft them into mice. This procedure led to the growth of human tumours in mice. Cancer stem cells were identified in these tumours and it was shown that only the cancer stem cells and not the other cancer cells led to the development of new tumours upon grafting into additional mice. This process could be repeated multiple times and the animals could be used to study the development of cancer and test the action of potential new cancer drugs against Wilms' tumours.

"We identified several biomarkers, including molecules that are on the cell surface, cell signaling molecules and microRNAs, that make it possible to distinguish between cancer stem cells or cancer-initiating cells and the rest of the cells in the tumour that are less likely to lead to cancer. In further experiments, we were able to show that an antibody drug that targets one such biomarker, the neural cell adhesion molecule, was able to either almost completely or in some cases completely eradicate the tumours that we induced in mice," added Dekel. "This preliminary result suggests that the cancer stem cells that we have identified, isolated and propagated may serve as a useful tool to look for new drug targets as well as new drugs for the treatment of Wilms' tumours."

Further work is needed to identify more precisely how the antibody drug used in the study (lorvotuzumabmertansine) affects cancer stem cell populations and to test the long-term suitability of the antibody drug to treat Wilms' tumours in humans.


Contact: Barry Whyte
European Molecular Biology Organization

Related biology news :

1. Emerging virus in raccoons may provide cancer clues
2. Vaccine offers promise as post-surgery treatment for pancreatic cancer patients
3. Predictors of cancer disease progression improve patient selection for metastasis-directed therapy
4. Biologists engineer algae to make complex anti-cancer designer drug
5. Fred Hutchinson Cancer Research Center partners with GlaxoSmithKline to develop muscular dystrophy therapeutics
6. Stem cell research provides hope for infertile cancer survivors
7. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
8. Clinical trial tests rice bran to prevent cancer
9. Nanotechnology drug delivery shows promise for treatment of pediatric cancer
10. Predicting the age at menopause of women having suffered from childhood cancers
11. Research shows immune system response is detrimental to novel brain cancer therapy
Post Your Comments:
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
(Date:10/29/2015)... RESTON, Va. , Oct. 29, 2015 ... announced today that it has released a new version ... Daon customers in North America ... gains. IdentityX v4.0 also includes a FIDO UAF ... customers are already preparing to activate FIDO features. These ...
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... a partnership with 2XU, a global leader in ... a smart hat with advanced bio-sensing technology. The ... athletes to monitor key biometrics to improve overall ... partnership, the two companies will bring together the most ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the ... C.W. Wong to its Board of Directors to replace ... with a wealth of experience as co-founder of Resverlogix, with ... --> --> Dr. Wong remarked, ... of directors. Zenith,s long standing expertise in epigenetics and the ...
(Date:11/30/2015)... -- TapImmune, Inc. (TPIV), a clinical-stage ... and gene-based immunotherapeutics and vaccines for the treatment of ... presenting at the 8 th Annual LD Micro ... PT. Dr. John N. Bonfiglio a TapImmune ... presentation and will join TapImmune management in meeting with ...
(Date:11/30/2015)... 2015  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW ... therapies for solid tumor cancers, announced today that the ... and the Company welcomes Neil Woodford,s call ... anonymous internet report on NW Bio.  The Company,s Board ... Powers stated, "We agree with Mr. Woodford that, ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, ... applied spectroscopy, covers a wide range of applications such as, but not limited ...
Breaking Biology Technology: